Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder (PTSD). The invention, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," encompasses both composition and method claims for the company's proprietary approach to preventing or delaying stress-induced behavioral responses. This U.S. patent allowance follows a corresponding patent issued by the Japan Patent Office earlier this year, signaling growing international recognition of Silo's innovative work in stress-induced psychiatric disorders.
A Notice of Allowance indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly. For Silo Pharma, this development is crucial as it advances SPC-15 through the development pipeline. "The U.S. patent protection is an important component of our strategy as we advance SPC-15 development for PTSD," the company stated, adding that it adds to its biopharmaceutical intellectual property portfolio of issued and allowed patents. The patent, once granted, will provide Silo with exclusive rights to the composition and methods of use for SPC-15 in the United States, potentially blocking competitors from marketing similar therapies and enhancing the company's ability to attract partners or investors.
The implications of this patent allowance extend beyond legal protection. PTSD is a debilitating condition that affects millions of people worldwide, with current treatments often limited by side effects or inadequate efficacy. SPC-15 is designed as an intranasal formulation, which may offer advantages such as rapid absorption and direct targeting of the central nervous system. By securing patent rights, Silo Pharma is positioning itself as a key player in the development of novel PTSD therapies, a market that remains underserved despite significant demand. The company's focus on stress-induced psychiatric disorders, chronic pain, and CNS diseases aligns with its mission to address conditions with high unmet need.
Silo Pharma's broader portfolio includes other innovative programs such as SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories, underscoring the company's commitment to scientific rigor. The patent allowance for SPC-15 not only validates the company's proprietary approach but also strengthens its competitive edge in the biopharmaceutical landscape. For investors, this milestone may signal progress toward potential commercialization, although clinical trials and regulatory approvals remain ahead. The full press release can be viewed at https://ibn.fm/Hh4Z6.
In an industry where intellectual property is often the cornerstone of value, Silo Pharma's successful patent prosecution in both the U.S. and Japan demonstrates its ability to secure rights to its innovations. This could facilitate partnerships or licensing deals with larger pharmaceutical companies seeking to expand their neuroscience portfolios. Moreover, the patent allowance may boost investor confidence by reducing the risk of generic competition early in the product lifecycle. As Silo continues to advance SPC-15, the patent will serve as a foundation for potential future revenue streams, provided the therapy succeeds in clinical trials. The company's newsroom, available at https://ibn.fm/SILO, provides ongoing updates on its progress.
